Sign in
Not yet taking people in ChinaPhase 1/2

Tests HRS-1738 imaging to help detect prostate cancer

Tests the safety of HRS-1738 PET scan imaging in adults with prostate cancer.

Key facts

Who runs it
Jiangsu HengRui Medicine Co., Ltd.
Where
Beijing, ChinaSee the site
Trial code
Registry title
Phase I/II Clinical Study of HRS-1738 for the Diagnosis of Prostate Cancer Patients
Status
Not yet recruiting
Phase
Phase 1/2
People taking part
50 people, planned
Started
Jul 2025
Planned end
Aug 2026
Type of study
Interventional
Treatments tested
  • HRS-1738 Injection
Record updated
9 July 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adult men with prostate cancer confirmed by tissue testing. It tests the safety of HRS-1738 injection and how well it works in PET/CT scans.

Age
18 years or older
Sex
Men only
Disease stage
Prostate adenocarcinoma confirmed by histopathology; ECOG performance score of 0 or 1
Earlier treatment
At least 12 weeks since the most recent surgery (8 weeks may be allowed if the patient has recovered). Side effects of earlier cancer treatment must have recovered to grade 1 or lower. At least 4 weeks since the end of any previous clinical study drug.

Main reasons for not taking part

  • Known HIV infection, active hepatitis B or C, or active syphilis
  • Severe or poorly controlled body-wide disease (such as heart failure or a heart attack within 6 months)
  • Cannot lie flat or stay still for a PET/CT scan, or has metal implants or joint prostheses
  • Another primary cancer apart from prostate cancer, with a few low-risk exceptions
  • Allergy to the study drug, or a history of epilepsy, dementia or other neurological or mental disorders

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Be able to understand and abide by the procedures and requirements of this study and voluntarily sign the informed consent form
  • Male, aged ≥18 years old
  • ECOG (Eastern Oncology Collaboration) Physical Condition score: 0 or 1
  • Prostate adenocarcinoma confirmed by histopathology
  • The distance between enrollment and the most recent surgical treatment should be at least 12 weeks. If the patient has recovered from the surgery before enrollment and meets other enrollment criteria, it can be relaxed to 8 weeks as determined by the investigator
  • The functions of the major organs should meet the requirements
  • For male subjects, they need to agree to take effective contraceptive measures with their partners within one week after the last administration of the investigational drug from the date of signing the informed consent form, and have no plans for fertility and do not donate sperm

Who cannot take part

  • Combined with the following diseases:; . Severe urinary incontinence, hydronephrosis, severe urinary dysfunction, etc. Note: Subjects with bladder outflow tract obstruction or urinary incontinence who can be controlled through the existing best standard treatment (including urinary pads, drainage, etc.) are eligible to participate in the study; . Concurrent active infection or unexplained fever >38.5℃ for more than 1 hour during the screening period and before administration; . Combined with severe or poorly controlled systemic diseases, including but not limited to poorly controlled diabetes, congestive heart failure, unstable angina pectoris, myocardial infarction that occurred within 6 months before administration, refractory hypertension, acute kidney injury, stroke, and severe liver injury; . Combined with active hepatitis B (HBV-DNA testing is required for HBsAg positive patients, and HBV DNA≥2000 IU/mL or 104 copies/mL), active hepatitis C (HCV-Ab positive and higher than the detection limit of the analytical method); . Those who are known to have tested positive for acquired immunodeficiency syndrome (AIDS) or human immunodeficiency virus (HIV); . Active syphilis infected individuals
  • There are any factors that prevent the smooth progress of PET/CT examination or interfere with the interpretation of imaging results, including but not limited to the following situations: such as inability to lie flat, remain still or tolerate PET/CT scanning; It is known that there are metal implants or joint prostheses, etc
  • Participating in other clinical studies or having less than 4 weeks since the end of the last administration of the previous clinical study at the time of the first administration
  • It is known that there is an allergy or contraindication to any component of the test drug or its preparation
  • Patients who had a second primary malignant tumor other than prostate cancer before enrollment, excluding malignant tumors with a low risk of metastasis and death that have been cured (5-year survival rate >90%), such as superficial squamous cell carcinoma of the skin, low-grade superficial bladder cancer, etc
  • History of neurological or mental disorders, including epilepsy or dementia
  • According to the NCI-CTCAE v5.0 classification, those whose toxicity caused by previous anti-tumor treatment has not yet recovered to grade ≤1 (except for decreased lymphocyte count alone, alopecia, and the indicators mentioned in the inclusion criteria; According to the judgment of the researchers, after consultation with the sponsor, some tolerable chronic grade 2 toxicities may be excluded

Where in China

  • Beijing Cancer HospitalBeijing, ChinaContact: Zhi YangNot yet recruiting

About the trial

What the trial wants to find out

This study aims to evaluate the safety and pharmacokinetics of HRS-1738 injection in adult patients with prostate cancer.

The group in the trial

  • HRS-1738 GroupTreatment being tested

    Treatment: HRS-1738 Injection

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase I/II Clinical Study to Evaluate the Safety, Pharmacokinetics, Radiation Dosimetry and Preliminary Diagnostic Efficacy of HRS-1738 in PET/CT Imaging of Patients With Prostate Cancer
Plain-language title
Tests HRS-1738 imaging to help detect prostate cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
9 July 2025